Pherecydes Pharma Overview
- Founded
-
2006

- Status
-
Public
- Employees
-
27

- Stock Symbol
-
ALPHE

- Share Price
-
$2.45
- (As of Monday Closing)
Pherecydes Pharma General Information
Description
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on various bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.
Contact Information
Website
www.pherecydes-pharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Primary Office
- 22 Boulevard Bénoni Goullin
- 44200 Nantes
- France
+33 01 00 00 00 00
Pherecydes Pharma Timeline
Pherecydes Pharma Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.45 | $2.44 | $1.92 - $7.86 | $17.6M | 7.19M | 3.51K | -$0.54 |
Pherecydes Pharma Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 22,309 | 39,313 | ||
Revenue | 2,413 | 2,533 | 2,060 | 2,531 |
EBITDA | (5,043) | (4,921) | (3,692) | (2,747) |
Net Income | (3,145) | (3,770) | (1,591) | (1,368) |
Total Assets | 14,213 | 15,947 | 9,688 | 7,837 |
Total Debt | 2,494 | 2,744 | 492 | 1,342 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Pherecydes Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Pherecydes Pharma Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Pherecydes Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on va
Drug Discovery
Nantes, France
27
As of 2022
000.00
00.00
0000-00-00
000000000
000.00
Pherecydes Pharma Competitors (18)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
BiomX | Formerly VC-backed | Ness Ziona, Israel | 000 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
0000 00000000000 | Venture Capital-Backed | Somerville, MA | 0 | 000.00 | 0000000000 0 | 000.00 |
000000 00000000000 | Formerly VC-backed | Marina del Rey, CA | 00 | 00000 | 000000000 | 00000 |
00000 00000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
Pherecydes Pharma Patents
Pherecydes Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3054874-A1 | Phage therapy | Pending | 08-Mar-2017 | 000000000 | |
EP-3372085-A1 | Phage therapy | Inactive | 08-Mar-2017 | 000000000 | |
EP-3592150-A1 | Phage therapy | Pending | 08-Mar-2017 | 000000000 | |
JP-2020510024-A | Phage therapy | Pending | 08-Mar-2017 | 000000000 | 0 |
US-20200030392-A1 | Phage therapy | Pending | 08-Mar-2017 | A61K35/76 |
Pherecydes Pharma Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Didier Hoch | Chief Executive Officer & Chairman | ||
Thibaut Fayet | Chief Executive Officer | ||
Cindy Fevre Ph.D | Chief Scientific Officer |
Pherecydes Pharma Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Claire Poulard | Omnes Capital | Supervisory Board Member | 000 0000 |
Didier Hoch | Pherecydes Pharma | Chief Executive Officer & Chairman | 000 0000 |
Eric Leire MD | Self | Supervisory Board Member | 000 0000 |
Franck Lescure Ph.D | Auriga Partners (Paris) | Supervisory Board Member | 000 0000 |
Guy Rigaud | Self | Supervisory Board Member | 000 0000 |